News

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...
Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...
We estimated age-standardized cancer incidence (2010–2019) and mortality rates (2010–2022) in the United States to investigate whether cancer rates have increased at younger ages. Fourteen cancers had ...
Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous ...
AbstractPurpose:. Death receptor (DR)–targeted therapies offer a promising tumor cell–specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether ...
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...
AbstractRAS inhibition has the potential to transform cancer treatment for many patients. The landscape of RAS inhibitor therapies is rapidly evolving, with two mutant-selective KRAS inhibitors now ...
Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...
An Iranian missile hit the campus of Israel’s Weizmann Institute of Science, destroying many cancer research labs. Researchers mourned the loss of expensive equipment and irreplaceable samples and ...
Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...
AbstractBackground:. The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and the development of novel treatments, underscoring the need for ...